Problem

Proprio addresses a structural mismatch in surgery: the operating room is a dynamic, three-dimensional environment, while conventional navigation relies heavily on static images and fixed landmarks. That creates workflow constraints in complex cases and can require intraoperative imaging, exposing patients and staff to radiation, interrupting procedures, consuming capital equipment, and limiting operating-room capacity. Proprio positions the economic benefit around faster, more precise surgery: its materials say Paradigm can save up to 30 minutes per procedure while reducing imaging needs and improving access to care.

The primary use case is complex spine surgery, particularly navigation for implant and screw placement and difficult procedures such as scoliosis and collapsed discs. The pain is especially acute where surgeons must register preoperative plans to changing anatomy and verify alignment or progress during the operation; Proprio's goal is to make those decisions more measurable and less dependent on static views or educated guesswork.

Product / Service

The core product is Paradigm™, an FDA-cleared AI-powered surgical-navigation and guidance platform. It combines a multimodal sensor array, light-field and computer-vision technology, compute, and AI to fuse CT, MRI, operative plans, and live intraoperative views into a real-time 3D model of the anatomy. Surgeons receive continuous visualization, guidance, and intraoperative measurements through a heads-up display, including progress against the preoperative plan and feedback on whether surgical goals have been achieved.

Paradigm is an institution-facing medical-technology platform rather than simply a visualization tool: Proprio says every case generates structured surgical data that supports learning, documentation, training, quality programs, and clinical research. Its value proposition is to eliminate or reduce intraoperative imaging, accelerate registration and surgical steps, improve precision and patient outcomes, and help hospitals use their operating rooms and imaging infrastructure more efficiently. Available company-intelligence evidence describes revenue through direct partnerships and licensing agreements with healthcare institutions and surgical facilities, although the cited materials do not disclose pricing or revenue amounts.

Market

Proprio competes in surgical navigation and the emerging category of AI-enabled surgical guidance, initially focused on spine surgery. Its differentiated position is the combination of real-time 3D, light-field sensing, multimodal data fusion, intraoperative measurement, and an accumulating surgical-data layer. The broader navigation market includes established players such as Medtronic and Brainlab, as well as B. Braun and other medical-device companies; these are relevant incumbents and alternatives, though the evidence does not establish that every listed company offers an identical product to Paradigm.

The company has progressed beyond a purely pre-revenue or development-stage profile. Paradigm received its first FDA 510(k) clearance in 2023 and a second major clearance in April 2025 for intraoperative measurements. Proprio reported 50 completed surgeries by October 2024, including hundreds of implants across challenging cases, and said the platform was expanding to leading hospitals in the United States and abroad; its 2025 announcement identified Duke Health and UW Medicine as initial spine centers. It also raised a $43 million Series B in 2023 to fund commercialization, while third-party company intelligence says it generates revenue through institutional partnerships and licensing. No public revenue figure is provided in the available evidence.